Absci Corporation

Absci Corporation is a pioneering drug creation company leveraging a data-first, generative artificial intelligence approach to accelerate the discovery and development of novel antibody therapeutics. The company's innovative platform integrates advanced AI algorithms with high-throughput wet lab capabilities, enabling the design of highly differentiated and potentially more effective drug candidates. Absci's business model centers on utilizing its proprietary AI technology to identify and optimize antibody sequences, significantly reducing the time and cost traditionally associated with drug discovery. Their preclinical pipeline features promising candidates targeting significant unmet medical needs, including ABS-101 for inflammatory bowel disease, ABS-201 for androgenic alopecia, ABS-301 for immuno-oncology applications, and ABS-501 for various oncology indications. Absci actively pursues strategic collaborations with leading organizations across the life sciences and technology sectors, including PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. These partnerships are crucial for expanding their research capabilities, accessing diverse datasets, and validating their AI-driven drug design methodologies. By focusing on the intersection of AI and biologics, Absci aims to establish a leadership position in the rapidly evolving field of AI-powered drug discovery and development.